Thomas Serwold

Title: Thomas Serwold: Innovator in Immunotherapy

Introduction

Thomas Serwold is a notable inventor based in Boston, MA (US). He has made significant contributions to the field of immunotherapy, particularly through his innovative patent that focuses on redirecting cells with MHC chimeric receptors. His work has the potential to enhance the specificity and effectiveness of T cell therapies.

Latest Patents

Thomas Serwold holds a patent titled "Redirected cells with MHC chimeric receptors and methods of use in immunotherapy." This patent describes chimeric receptors that feature major histocompatibility molecules grafted onto T cell receptor molecules. Additionally, it includes surrogate co-receptors that feature cell surface receptor ligands fused with signaling molecule domains. The chimeric receptors can be utilized to redirect cells, altering their specificity. T cells expressing these chimeric receptors may bind to ICRs of target T cells for which their chimeric receptors are specific. Surrogate co-receptors can enhance TCR-CD3 signaling as part of this modular receptor system. This innovative approach may help eliminate autoreactive T cells or program T cells to desired effector functions. Thomas Serwold has 1 patent to his name.

Career Highlights

Throughout his career, Thomas Serwold has worked with esteemed organizations, including the Arizona Board of Regents on Behalf of the University of Arizona and Joslin Diabetes Center, Inc. His experience in these institutions has allowed him to collaborate with leading experts in the field of immunotherapy.

Collaborations

One of his notable coworkers is Michael S. Kuhns, with whom he has likely shared insights and advancements in their research endeavors.

Conclusion

Thomas Serwold's contributions to immunotherapy through his innovative patent demonstrate his commitment to advancing medical science. His work has the potential to significantly impact the treatment of various diseases, showcasing the importance of innovation in healthcare.